Bruker Valuation
Is BRKR * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of BRKR * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BRKR * (MX$1372.36) is trading below our estimate of fair value (MX$1969.06)
Significantly Below Fair Value: BRKR * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BRKR *?
Other financial metrics that can be useful for relative valuation.
What is BRKR *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$11.00b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 4.1x |
Enterprise Value/EBITDA | 21.7x |
PEG Ratio | 4.1x |
Price to Earnings Ratio vs Peers
How does BRKR *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 54.3x | ||
CRL Charles River Laboratories International | 23.9x | 12.5% | US$10.8b |
TECH Bio-Techne | 56.7x | 16.2% | US$11.7b |
ERF Eurofins Scientific | 34.6x | 20.2% | €8.9b |
SRT3 Sartorius | 101.8x | 27.9% | €13.7b |
BRKR * Bruker | 27.4x | 6.8% | Mex$11.0b |
Price-To-Earnings vs Peers: BRKR * is good value based on its Price-To-Earnings Ratio (27.4x) compared to the peer average (51.9x).
Price to Earnings Ratio vs Industry
How does BRKR *'s PE Ratio compare vs other companies in the Global Life Sciences Industry?
Price-To-Earnings vs Industry: BRKR * is good value based on its Price-To-Earnings Ratio (27.4x) compared to the Global Life Sciences industry average (32.2x).
Price to Earnings Ratio vs Fair Ratio
What is BRKR *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 27.4x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BRKR *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.